共 63 条
[1]
Shirasaka T(1996)Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drug 7 548-557
[2]
Shimamoto Y(2011)Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer: a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Eur J Cancer 47 2306-2314
[3]
Ohshimo H(2012)Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone J Clin Oncol 30 1513-1518
[4]
Thuss-Patience PC(2013)Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial J Clin Oncol 31 4438-4444
[5]
Kretzschmar A(2004)Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine -dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model Int J Oncol 25 1531-1536
[6]
Bichev D(2008)Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts Ann Surg Oncol 15 2301-2309
[7]
Kang JH(2007)Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002) Oncology 73 65-71
[8]
Lee SI(2008)Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer Oncology 74 37-41
[9]
Lim DH(2006)Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer Clin Cancer Res 12 3402-3407
[10]
Hironaka S(2003)Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial J Clin Oncol 21 2059-2069